---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-24-000117"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:45:08.709830+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end

## Summary
- PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.
- Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.
- Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.
- Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.
- Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025.

## SEC filing metadata
- accession: 0001439222-24-000117
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/0001439222-24-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000117/agio-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-24-000117
- JSON: https://secwatch.observer/filing/0001439222-24-000117.json
- Plain text: https://secwatch.observer/filing/0001439222-24-000117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.